ClinicalTrials.gg
RecruitingNCT07647640BYODUpdated Oct 13, 2026

Prospective Evaluation of Flare Detection in IBD With Digital Biomarkers: Bring Your Own Device Study

An observational study in Inflammatory Bowel Disease (IBD), Ulcerative Colitis (UC) and Crohn Disease (CD), sponsored by Maastricht University Medical Center. Recruiting at 3 sites in Netherlands. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-13.

Sponsored by Maastricht University Medical Center · Observational

How we know

From the registry’s dates

  • Started Aug 2026; still recruiting 3 months later.
Updated Oct 13, 2026Now RecruitingSite recruiting status changed+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
600
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 79 studies in Inflammatory Bowel Diseases with a site in Netherlands — 22 open to participants now, 28 under way, 7 of them phase 3. Inflammatory Bowel Diseases · Netherlands.

Planned enrollment
7th of 18
600 · median 378
Started
2026
with 2 others
Observational
18 of 79
4 open now
Primary completion
2027-12
later than 22 of 27 live
Registered
79th of 79
by date
Lead sponsor
9 of 79
Maastricht University Medical Center

Among the 79 studies in Inflammatory Bowel Diseases with a site in Netherlands, this one is the 7th largest by planned enrollment of the 18 observational ones that give a count, is one of 3 that started in 2026, is one of 18 observational ones, reaches primary completion later than 22 of the 27 other live ones, and was the 79th registered.

Inflammatory Bowel Diseases

1,555 studies on the registry are indexed under Inflammatory Bowel Diseases; 425 are open to participants now.

Browse Inflammatory Bowel Diseases studies →

Open to participants now

22 of the 79 studies in Inflammatory Bowel Diseases with a site in Netherlands are open now. Recruiting first, the newest first:

16 more — sign in →

All 22 open studies →

A study can be open while its sites in Netherlands have not opened yet or have stopped. Only those recruiting at a site in Netherlands →

Who these studies take

Of the 276 Inflammatory Bowel Diseases studies recruiting now, 134 (49%) set no upper age limit and 114 (41%) stop at 75 or younger; 75 take children under 18; 60 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 79 studies in Inflammatory Bowel Diseases with a site in Netherlands, or all of them as a file.
02

Study summary

The aim of this study is to identify HRV changes predictive of IBD flares using patient-own wearable devices in a large cohort supplemented by additional data layers including sleep parameters, step count and clinical data extracted from electronic patient files.

Read the detailed description

IBD, comprising Crohn's disease and ulcerative colitis, is a chronic inflammatory condition of the gastrointestinal tract, with a globally rising prevalence. Current medical care consists of outpatient visits combined with blood and stool tests, radiological examination and endoscopy. The disease is costly to manage, also leading to indirect costs such as reduced work productivity. Telemonitoring platforms, including MyIBDCoach, IBD@home(Luscii) and IBDream, can alleviate these factors by enabling remote cost-effective monitoring of patient's health. However, data collection largely relies on burdensome questionnaires which are susceptible to bias. Emerging technologies such as wearable devices and smartphones enable continuous remote monitoring through digital biomarkers. This Bring Your Own Device (BYOD) study is part of the IBDigital project, which aims to enrich existing monitoring platforms by integrating digital biomarkers.

In this prospective, observational, multicenter cohort study, patients with IBD will be recruited from the outpatient clinics of the participating centers. Data will be collected from participants' personal smartwatches (and smartphones). Following an inclusion period of approximately four months, participants will enter a one-year follow-up period. During follow-up, standard-of-care clinical data will be collected during outpatient visits. In addition, wearable-derived data, including heart rate metrics, sleep parameters, and physical activity measures, will be continuously collected.

03

Conditions studied

  • Inflammatory Bowel Disease (IBD)
  • Ulcerative Colitis (UC)
  • Crohn Disease (CD)

Keywords

  • Inflammatory Bowel Disease
  • Digital biomarkers
  • Heart rate variability
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Patients from MyIBDCoach, IBDream cohort and IBDthuis (Luscii cohort) with ulcerative colitis or Crohn's Disease.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 18 years or older
  • Crohn's Disease or ulcerative colitis
  • Having a smartwatch and/or a smartphone
  • Apple watch, Samsung Watch, Fitbit, Garmin, Polar (devices will not be made available)

Exclusion criteria

Exclusion Criteria:

  • No specific exclusion criteria will be used. Subgroup analysis will be performed for patients with e.g. heart problems or arrhythmia, medication impacting HR (such as beta blockers), pregnancy, thyroid problems, shift work...
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
600 participants (estimated)
Patient registry
No

Groups and cohorts

  • Patients with IBD

    ≥18 years or older with Crohn's disease or ulcerative colitis, and having a smartwatch (Apple watch, Samsung Watch, Fitbit, Garmin, Polar (devices will not be made available) ) and/or a smartphone.

    Device: Wearing their own wearable device.

Interventions

  • DeviceWearing their own wearable device.

    Wearing their own wearable device.

06

What researchers measure

Primary outcomes

  1. Prediction of mucosal inflammation (calprotectin≥250 µg/g and/or CRP≥5mg/l with UCEIS≥1 or Mayo≥1 (UC) and SES CD≥3 (CD) on endoscopic/radiological evaluation) using HRV-changes relative to individual baseline.

    Time frame: 1 year

Secondary outcomes

  1. Prediction of mucosal inflammation (assessed by laboratory tests and/or imaging in IBD) using changes in physical activity and sleep metrics relative to individual baseline.

    Time frame: 1 year

  2. Identification of a discrepancy between inflammatory flares and symptomatic flares (MIAH-CD>3.6 and MIAH-UC>3.5) regarding HRV.

    Time frame: 1 year

  3. To study the inter-device variability in mean HRV metrics (including MESOR, acrophase, amplitude, SDNN, RMSSD), PA and sleep parameters, compared to resting state.

    Time frame: 1 year

  4. Investigation of additional digital phenotypes that can be derived from the available (wearable/clinical) data and how these phenotypes differ across relevant subgroups within the study population.

    Time frame: 1 year

  5. To study the difference in step count measured by smartwatches compared with smartphones.

    Time frame: 1 year

  6. To investigate if changes in HRV, PA and sleep relative to baseline predict clinical/symptomatic remission in IBD.

    Time frame: 1 year

07

Study locations

2 of 3 sites recruiting
08

References and documents

Publications

  • Leung W, Case L, Jung J, Yun J. Factors associated with validity of consumer-oriented wearable physical activity trackers: a meta-analysis. J Med Eng Technol. 2021 Apr;45(3):223-236. doi: 10.1080/03091902.2021.1893395. Epub 2021 Mar 22. PubMed 33750250 ↗
  • Kaplan GG. The global burden of inflammatory bowel disease: from 2025 to 2045. Nat Rev Gastroenterol Hepatol. 2025 Oct;22(10):708-720. doi: 10.1038/s41575-025-01097-1. Epub 2025 Jul 18. PubMed 40681759 ↗
  • Bossuyt P, De Nollin I, De Moor T, Trekels G, Maes I, Dewulf G, Pouillon L. Inflammation Is a Large Dataset of Heartbeats, Groceries, Night Rest, and More. Gastroenterology. 2025 Oct;169(5):1085-1086. doi: 10.1053/j.gastro.2025.05.029. Epub 2025 Jun 25. No abstract available. PubMed 40578576 ↗
  • de Jong MJ, Boonen A, van der Meulen-de Jong AE, Romberg-Camps MJ, van Bodegraven AA, Mahmmod N, Markus T, Dijkstra G, Winkens B, van Tubergen A, Masclee A, Jonkers DM, Pierik MJ. Cost-effectiveness of Telemedicine-directed Specialized vs Standard Care for Patients With Inflammatory Bowel Diseases in a Randomized Trial. Clin Gastroenterol Hepatol. 2020 Jul;18(8):1744-1752. doi: 10.1016/j.cgh.2020.04.038. Epub 2020 Apr 23. PubMed 32335133 ↗
  • de Jong M, van der Meulen-de Jong A, Romberg-Camps M, Degens J, Becx M, Markus T, Tomlow H, Cilissen M, Ipenburg N, Verwey M, Colautti-Duijsens L, Hameeteman W, Masclee A, Jonkers D, Pierik M. Development and Feasibility Study of a Telemedicine Tool for All Patients with IBD: MyIBDcoach. Inflamm Bowel Dis. 2017 Apr;23(4):485-493. doi: 10.1097/MIB.0000000000001034. PubMed 28267047 ↗
  • Hirten RP, Danieletto M, Scheel R, Shervey M, Ji J, Hu L, Sauk J, Chang L, Arnrich B, Bӧttinger E, Dudley J, Keefer L, Sands BE. Longitudinal Autonomic Nervous System Measures Correlate With Stress and Ulcerative Colitis Disease Activity and Predict Flare. Inflamm Bowel Dis. 2021 Oct 18;27(10):1576-1584. doi: 10.1093/ibd/izaa323. PubMed 33382065 ↗
  • Hirten RP, Danieletto M, Sanchez-Mayor M, Whang JK, Lee KW, Landell K, Zweig M, Helmus D, Fuchs TJ, Fayad ZA, Nadkarni GN, Keefer L, Suarez-Farinas M, Sands BE. Physiological Data Collected From Wearable Devices Identify and Predict Inflammatory Bowel Disease Flares. Gastroenterology. 2025 May;168(5):939-951.e5. doi: 10.1053/j.gastro.2024.12.024. Epub 2025 Jan 16. PubMed 39826619 ↗

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2026 (actual). Primary completion is estimated for Dec 2027, 16 months after the start.

Of 244 non-industry observational studies under Inflammatory Bowel Diseases, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 132. This study's planned 16 months is below that.

Counting every sponsor, half of 281 studies reached it within 36 months; a quarter within 20 and three quarters within 122.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 13, 2026: start Jun 2026 → Aug 2026, primary completion Oct 2027 → Dec 2027 and completion Oct 2027 → Dec 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jun 9, 2026
First posted
Jun 15, 2026
StartActual
Aug 4, 2026was Jun 2026
Primary completionEst.
Dec 15, 2027was Oct 2027
CompletionEst.
Dec 15, 2027was Oct 2027
Last update
Oct 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Oct 13, 2026
Sites
3 sites changed recruiting status (2 now recruiting, 1 now not yet recruiting)
Show 3 sites
  • Jeroen Bosch Hospital · 's-Hertogenbosch, Netherlandsno status→Recruiting
  • Maastricht UMC+ · Maastricht, Netherlandsno status→Recruiting
  • Franciscus Hospital · Rotterdam, Netherlandsno status→Not yet recruiting
Oct 13, 2026
Start date
Jun 15, 2026→Aug 4, 2026 (actual)
Oct 13, 2026
Primary completion
Oct 15, 2027→Dec 15, 2027
Oct 13, 2026
Study completion
Oct 15, 2027→Dec 15, 2027
Oct 13, 2026
Show all 1 update
  1. Oct 13, 2026
    Not yet recruiting→Recruiting
    3 sites changed recruiting status (2 now recruiting, 1 now not yet recruiting)
    Show 3 sites
    • Jeroen Bosch Hospital · 's-Hertogenbosch, Netherlandsno status→Recruiting
    • Maastricht UMC+ · Maastricht, Netherlandsno status→Recruiting
    • Franciscus Hospital · Rotterdam, Netherlandsno status→Not yet recruiting
    Start date Jun 15, 2026→Aug 4, 2026 (now actual)
    Primary completion Oct 15, 2027→Dec 15, 2027
    Study completion Oct 15, 2027→Dec 15, 2027
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07647640
Collaborators
Maastricht University, TNO, Franciscus Gasthuis & Vlietland (Hospital), Jeroen Bosch Ziekenhuis, s'-Hertogenbosch
Responsible party
Sponsor
First posted
Jun 15, 2026
Start date
Aug 4, 2026
Primary completion
Dec 15, 2027 (estimated)
Completion
Dec 15, 2027 (estimated)
Last update
Oct 13, 2026

Study contacts

E Godecharle, MD
Contact
eline.godecharle@maastrichtuniversity.nl
+31 43 388 50 65
MJ Pierik, Prof. Dr.
principal investigator · Maastricht UMC

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion